08 November 2021
EMA/632964/2021
EMEA/H/C/001107

Public statement

Docetaxel Teva

Withdrawal of the marketing authorisation in the European Union

On 11 October 2021, the European Commission withdrew the marketing authorisation for Docetaxel Teva (docetaxel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Docetaxel Teva was granted marketing authorisation in the EU on 26 January 2010 for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Docetaxel Teva is a generic medicine of Taxotere. There are other generic medicinal products of Taxotere authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Docetaxel Teva will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union